Bio Diagnostics Businesses for Sale and Investment

The company has pioneered the first blood-based cancer detection tests capable of identifying up to 30 common cancers. - We have consistently focused on innovative solutions for early-stage cancer detection to significantly reduce cancer-related deaths. - The company employs an ingenious approach that combines cutting-edge experimental tools with the latest advancements in deep learning methodologies. - With the global rise in cancer incidence, annual cancer deaths have also increased significantly. - Most cancers are diagnosed at late stages due to the absence of early clinical symptoms, leading to poor prognosis. - Early detection of cancer can reduce mortality by up to 70%, yet no current methods accurately detect cancer at early stages. - We have leveraged this opportunity by developing a groundbreaking blood test that detects 30 cancers in both males and females. - Our product integrates molecular mapping of the physiological state with a deep learning platform to identify cancer-specific molecular signatures. - The test is a novel, non-invasive blood-based screening method capable of detecting cancers and identifying the tissue of origin from the same sample. - The 30 cancers detected represent about 90% of new cancer cases each year. - Our test has achieved an unmatched accuracy of over 98% for early-stage cancer detection. - This advancement can significantly reduce the global cancer mortality burden. - The company is in the process of commercializing the test. - The promoter have over 40+ years of experience in the industry. - Licenses include CIN, SSM and GST. We have also applied for a USFDA. We have applied to the DCGI (Drugs Controller General of India) for market approval in India. We will launch operations post the DCGI approval. - Our target audience includes hospitals in India and Singapore. - Our R&D headquarters are in Haryana, with global headquarters in Singapore. - We also maintain an office in Singapore with dedicated staff.

The company has pioneered the first blood-based cancer detection tests capable of identifying up to 30 common cancers. - We have consistently focused on innovative solutions for early-stage cancer detection to significantly reduce cancer-related deaths. - The company employs an ingenious approach that combines cutting-edge experimental tools with the latest advancements in deep learning methodologies. - With the global rise in cancer incidence, annual cancer deaths have also increased significantly. - Most cancers are diagnosed at late stages due to the absence of early clinical symptoms, leading to poor prognosis. - Early detection of cancer can reduce mortality by up to 70%, yet no current methods accurately detect cancer at early stages. - We have leveraged this opportunity by developing a groundbreaking blood test that detects 30 cancers in both males and females. - Our product integrates molecular mapping of the physiological state with a deep learning platform to identify cancer-specific molecular signatures. - The test is a novel, non-invasive blood-based screening method capable of detecting cancers and identifying the tissue of origin from the same sample. - The 30 cancers detected represent about 90% of new cancer cases each year. - Our test has achieved an unmatched accuracy of over 98% for early-stage cancer detection. - This advancement can significantly reduce the global cancer mortality burden. - The company is in the process of commercializing the test. - The promoter have over 40+ years of experience in the industry. - Licenses include CIN, SSM and GST. We have also applied for a USFDA. We have applied to the DCGI (Drugs Controller General of India) for market approval in India. We will launch operations post the DCGI approval. - Our target audience includes hospitals in India and Singapore. - Our R&D headquarters are in Haryana, with global headquarters in Singapore. - We also maintain an office in Singapore with dedicated staff.

Company and product: Enbiosis has developed an advanced artificial intelligence algorithm that analyzes the human gut microbiome and recommends personalized food and supplements to individuals to improve their gut health and address chronic disorders such as gastrointestinal disorders, skin-related disorders, and weight loss issues. - How it works: Patients/customers send their stool samples to any NGS laboratory in their region. Enbiosis takes the raw bacterial DNA data to the local server (to avoid data protection risks) and creates a personalized report, which is sent to patients and, if required, their practitioners within minutes. - Business model: Enbiosis's microbiome test can be sold through practitioners and/or directly to customers, depending on market dynamics. Practitioners can prescribe the test to patients to generate a personalized diet plan, or patients can follow their personalized nutrition guide through the app to improve general well-being and solve their problems. - Main differentiation: Enbiosis is the only clinically proven precision diet technology that claims to address the main cause of chronic disorders. It has conducted three clinical trials and published the results in peer-reviewed journals. Enbiosis's claims are backed by scientific evidence. - The main reason why investors should consider Enbiosis: In recent years, the number of people seeking to address their health problems through alternative methods instead of pharmaceuticals has been increasing. The challenge in alternative medicine is the lack of scientific data. Enbiosis serves as a bridge between alternative medicine and conventional medicine, and there is significant market potential for Enbiosis. For example, Enbiosis has proven the effectiveness of its technology in patients with IBS, who make up about 10% of the population. Offering individuals the opportunity to solve their chronic problems simply by changing their diet within a specific period is something they are interested in and willing to try. - Additionally, investors/distributors can offer a routine follow-up program to check gut health and prevent any kind of diseases, opening the door to long-term recurring revenue. - We have a trade registration certificate to operate.

Our company is essentially a biotechnology organization that sells proprietary diagnostic kits for healthcare and biotechnology research kits along with services. - These kits allow our customers to evaluate various parameters by themselves. - We have more than 40 in-house researched products. Manufacturing is done at our own premises. - Our products are sold to 32 distributors who further sell them at pharmacies and hospitals across India. Kits are also sold in Saudi Arabia, Dubai, Ukraine, Sudan and Zimbabwe. We do not sell our products directly to any customers. - Revenue plummeted this year due to the effect of the pandemic on the market. - The business is extremely valuable due to our vast array of products, IP, and enormous growth potential in the future.

Deep biotech company incubated by a leading university. - We have developed a portable device with AI-powered image recognition capabilities that can analyze Full Blood Count tests. The device will help with monitoring a patient's health from home for conditions such as leukemia and other types of cancer. - Patient can run the tests from their home and once the sample is analyzed, the results are deployed to our platform (app and browser), which is only shared with the designated doctor. - We also provide sophistical tools that help the patient and doctors to track and monitor health over time. - Have our own production facility with a capacity for 100 devices per month and the development of the device is already complete. We have also applied for a patent in the UK. - Revenue model: We will charge a monthly subscription of GBP 1,000 for medical professionals and doctors, and GBP 100 for patients. - Cost of production of each unit is around GBP 1,200 and we have already targeted the production of 1,000 pieces for the launch. - Well-experienced team of experts and medical consultants with over 30 years of industry experience.